Monaco Asset Management Sam Esperion Therapeutics, Inc. Transaction History

Monaco Asset Management Sam

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	SELL	$0.73 - $3.08 $677,540 - $2.86 Million	-928,137 Reduced 79.21%	243,642 $728,000
Q3 2023 Nov 07, 2023	BUY	$0.96 - $1.79 $457,417 - $852,893	476,477 Added 68.53%	1,171,779 $1.15 Million
Q2 2023 Aug 08, 2023	BUY	$1.2 - $1.76 $662,328 - $971,414	551,940 Added 385.0%	695,302 $966,000
Q1 2023 May 11, 2023	SELL	$1.46 - $7.3 $477,037 - $2.39 Million	-326,738 Reduced 69.5%	143,362 $227,000
Q4 2022 Jan 31, 2023	BUY	$5.09 - $8.5 $1.07 Million - $1.79 Million	210,100 Added 80.81%	470,100 $2.93 Million
Q3 2022 Oct 31, 2022	BUY	$5.45 - $8.13 $476,875 - $711,375	87,500 Added 50.72%	260,000 $1.74 Million
Q2 2022 Aug 01, 2022	SELL	$4.77 - $6.67 $1.18 Million - $1.65 Million	-246,762 Reduced 58.86%	172,500 $1.1 Million
Q1 2022 May 09, 2022	SELL	$3.34 - $5.56 $269,664 - $448,903	-80,738 Reduced 16.15%	419,262 $1.95 Million
Q4 2021 Feb 04, 2022	BUY	$4.81 - $11.92 $2.41 Million - $5.96 Million	500,000 New	500,000 $2.5 Million

206

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $153M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Monaco Asset Management Sam, based on Form 13F filings with the SEC.

Stay updated on Monaco Asset Management Sam with notifications on news.